Business Context and Reporting Period
This summary covers the Form 10-Q filed by Owens & Minor, Inc. (Note: The request metadata listed "Accendra Health Inc," but the source text is for Owens & Minor, Inc.) for the quarterly period ended June 30, 2009. The company is a large accelerated filer incorporated in Virginia. In January 2009, the company exited its direct-to-consumer (DTC) distribution business, which is now reported as discontinued operations. The financial results reflect the integration of the acquired acute-care distribution business of The Burrows Company.
Key Financial Metrics
| Metric | Q2 2009 | Q2 2008 | YTD 6mo 2009 | YTD 6mo 2008 |
|---|---|---|---|---|
| Revenue | $2,013.8 million | $1,771.2 million | $3,962.4 million | $3,498.5 million |
| Gross Margin | $197.7 million (9.82%) | $175.3 million (9.90%) | $381.3 million (9.62%) | $345.6 million (9.88%) |
| Operating Earnings | $48.9 million (2.43%) | $43.1 million (2.43%) | $88.8 million (2.24%) | $86.1 million (2.46%) |
| Net Income | $23.6 million | $23.6 million | $37.6 million | $47.8 million |
| Diluted EPS | $0.57 | $0.57 | $0.90 | $1.15 |
| Cash from Operations (YTD) | $123.4 million | $75.5 million | ||
| Long-Term Debt | ||||
| Available Liquidity | $295.0 million (Revolving Credit Facility) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 13.7% in Q2 and 13.3% YTD compared to 2008. Approximately 70% of this growth is attributed to the Burrows acquisition and new business, with the remainder from existing customers.
- Margin Compression: Gross margin percentage declined slightly (8 basis points in Q2, 26 basis points YTD). This was driven by lower margins on Burrows-related sales, higher supplier price increases (increasing the LIFO provision), and revenue deferrals related to performance targets.
- Discontinued Operations: The company recorded a loss of $4.1 million in Q2 and $12.5 million YTD from discontinued operations (DTC business), compared to $0.8 million and $0.7 million in 2008. This includes charges for exiting the business, partially offset by a $3.2 million gain on the sale of DTC assets.
- Operating Expenses: SG&A expenses increased due to compensation, occupancy, and freight costs associated with the Burrows integration, partially offset by lower fuel costs.
Outlook, Risks, and Management Commentary
- Liquidity: Cash and cash equivalents increased to $14.7 million. The company has $200 million in senior notes (6.35% interest, maturing 2016) and a $306 million revolving credit facility with $295 million available. No borrowings were outstanding on the revolver as of June 30, 2009.
- Future Margins: Management noted a supplier intends to significantly reduce pricing on certain products in Q3 2009, which is expected to have a material positive impact on gross margin due to a decrease in the LIFO provision.
- Contingencies: The company has $18.4 million in contingent obligations related to customer performance targets, none of which are currently accrued as they are not considered probable. A California administrative review regarding sales tax incentives could result in a loss of less than $1.0 million or a gain exceeding $5.0 million.
- Risks: Key risks include dependence on specific customers and suppliers, changes in healthcare regulations, fuel price volatility, and the ability to successfully integrate acquisitions.
Investor Verification Checklist
- Verify the impact of the Burrows acquisition integration costs on future operating margins.
- Monitor the realization of the expected Q3 2009 gross margin improvement from supplier price reductions.
- Review the status of the California sales tax incentive review and potential financial impact.
- Assess the company's ability to meet performance targets on contracts with $18.4 million in contingent obligations.
- Confirm the timeline and costs associated with the full exit of the DTC business.